List of Excipients in Branded Drug BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE

Generic Drugs Containing BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE

Company	Ingredient	NDC	Excipient
West-Ward Pharmaceutical Corp	butalbital, acetaminophen, and caffeine	0143-0170	D&C RED NO. 33
West-Ward Pharmaceutical Corp	butalbital, acetaminophen, and caffeine	0143-0170	D&C YELLOW NO. 10
West-Ward Pharmaceutical Corp	butalbital, acetaminophen, and caffeine	0143-0170	FD&C RED NO. 40
West-Ward Pharmaceutical Corp	butalbital, acetaminophen, and caffeine	0143-0170	GELATIN
West-Ward Pharmaceutical Corp	butalbital, acetaminophen, and caffeine	0143-0170	MAGNESIUM STEARATE
West-Ward Pharmaceutical Corp	butalbital, acetaminophen, and caffeine	0143-0170	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE?

# Of NDCs	Excipient
1	ALCOHOL
1	AMMONIA
1	BUTYL ALCOHOL
26	CELLULOSE, MICROCRYSTALLINE
2	COLLOIDAL SILICON DIOXIDE
16	CROSCARMELLOSE SODIUM

Butalbital, Acetaminophen, and Caffeine Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Butalbital, acetaminophen, and caffeine is a mature, multisource prescription combination with limited conventional patent protection and meaningful opportunities in formulation differentiation. The commercial value is concentrated in reliable supply, tablet and capsule performance, preservative-free liquid development, excipient substitution, taste and swallowability improvements, and products designed to reduce formulation, quality, or regulatory risk.

What is the regulatory and commercial status of butalbital, acetaminophen, and caffeine?

The combination is an immediate-release oral product used primarily for tension or muscle-contraction headaches. Common strengths include:

Product type	Butalbital	Acetaminophen	Caffeine
Fioricet capsule	50 mg	300 mg	40 mg
Common generic tablet	50 mg	325 mg	40 mg
Common generic capsule	50 mg	300 mg or 325 mg	40 mg

Fioricet is associated with an older U.S. New Drug Application, NDA 016812. The active-ingredient combination has been marketed for decades, and conventional immediate-release versions are generally exposed to generic competition. The commercial opportunity is therefore formulation- and execution-led rather than based on basic composition-of-matter exclusivity.

Butalbital is a barbiturate and is federally controlled as a Schedule III substance when combined with nonnarcotic analgesics such as acetaminophen and caffeine. Controlled-substance ordering, storage, recordkeeping, distribution, and diversion controls materially affect manufacturers and wholesalers.[1]

FDA labeling warns about acetaminophen-related liver injury, dependence and withdrawal associated with butalbital, medication-overuse headache, and additive central nervous system depression.[2] These safety issues constrain aggressive product-positioning claims and increase the value of packaging, dosing clarity, and compliance-oriented product design.

What patents protect butalbital, acetaminophen, and caffeine products?

The core combination has little apparent patent value in the United States because the active ingredients and conventional immediate-release dosage forms have been known and marketed for many years. A generic manufacturer’s primary protection strategy is normally regulatory approval, manufacturing know-how, trade secrets, trademarks, supply reliability, and possible formulation-specific patents rather than a basic combination patent.

Orange Book status

The FDA Orange Book is the primary source for patents and regulatory exclusivity associated with approved drug products. A sponsor evaluating a new ANDA, 505(b)(2) application, or reformulation should review the current Orange Book record for the relevant reference product and NDA, rather than rely on historical patent databases.[3]

For a conventional generic version, the expected patent profile is:

Protection category	Commercial relevance
Active-ingredient patent	No meaningful remaining protection expected for the mature combination
Conventional immediate-release composition patent	Usually expired or unavailable
Method-of-use patent	Potentially relevant only if a sponsor develops a distinct, patentable indication or dosing method
Formulation patent	Possible for modified release, abuse deterrence, taste masking, liquid stability, or specialized excipients
Manufacturing patent	Possible for a differentiated process, impurity-control method, or continuous manufacturing approach
Trademark	Relevant to brand positioning but does not block an approved generic

Patent expiration dates should be confirmed against current USPTO records, Orange Book listings, and the specific reference product. A historical patent number without a current Orange Book listing is not sufficient evidence of a present market barrier.

When does butalbital, acetaminophen, and caffeine lose exclusivity?

Conventional products have already lost practical market exclusivity through long-standing generic availability. The relevant commercial question is not when the combination loses exclusivity, but whether a new dosage form, delivery system, or formulation earns new regulatory and patent protection.

A new sponsor may pursue:

• An ANDA for a therapeutically equivalent immediate-release tablet or capsule.
• A 505(b)(2) application for a novel liquid, orally disintegrating tablet, modified-release product, or abuse-deterrent formulation.
• A proprietary formulation supported by composition, process, or method-of-use patents.
• A private-label or contract-manufactured product using an approved generic formulation.

A 505(b)(2) product may obtain three years of FDA exclusivity for certain new clinical investigations essential to approval, but that exclusivity does not automatically create broad protection against all generic versions. Five-year new chemical entity exclusivity would generally not apply to this established combination.[4]

What excipients are used in existing products?

Existing immediate-release tablets and capsules typically use conventional excipients selected for low cost, manufacturability, content uniformity, and acceptable dissolution.

Representative excipients reported in product labeling include:

• Lactose monohydrate
• Microcrystalline cellulose
• Pregelatinized starch
• Corn or pharmaceutical starch
• Povidone
• Crospovidone
• Croscarmellose sodium
• Colloidal silicon dioxide
• Magnesium stearate
• Talc
• Sodium lauryl sulfate
• Gelatin for hard capsules
• Titanium dioxide
• FD&C and D&C colorants

The precise formula differs by manufacturer and dosage form. DailyMed labeling for marketed products should be used to identify the current inactive-ingredient profile for each reference and generic product.[5]

The formulation baseline is therefore crowded but technically unsophisticated. That creates room for improved excipient systems, although the clinical differentiation must be credible and the regulatory pathway must match the proposed benefit.

What excipient strategies offer the strongest commercial opportunity?

1. Direct-compression robustness

A direct-compression formula using microcrystalline cellulose, spray-dried lactose, mannitol, or co-processed excipients can reduce wet-granulation steps and improve production economics.

The technical challenge is content uniformity. Butalbital and caffeine are present at lower quantities than acetaminophen, and segregation can create potency variability. A robust platform should control:

• Particle-size distribution
• Bulk density
• Flowability
• Electrostatic behavior
• Blend segregation
• Lubrication sensitivity
• Tablet weight variation

Low-shear blending alone may be inadequate if the active ingredients have materially different densities or particle sizes. Ordered mixing, dry granulation, or co-processing can improve uniformity.

2. Acetaminophen load management

Acetaminophen represents the largest mass fraction in most formulations. It can create large tablets, high compression forces, capping, friability, and dissolution variability.

Useful excipient strategies include:

• High-functionality microcrystalline cellulose
• Co-processed cellulose and silicified systems
• Spray-dried mannitol
• Pregelatinized starch
• Crospovidone with optimized intragranular and extragranular placement
• Low-level colloidal silicon dioxide for flow improvement

The goal is to preserve rapid dissolution while reducing tablet size and manufacturing variability. A smaller tablet can support adherence and patient acceptance, but any size reduction must not compromise dose uniformity or mechanical strength.

3. Taste masking and orally disintegrating tablets

Taste masking is commercially relevant because butalbital and acetaminophen can produce an unpleasant oral profile. An orally disintegrating tablet may address patients with difficulty swallowing conventional tablets, but it introduces challenges:

• Rapid release of bitter or unpleasant actives
• Moisture sensitivity
• Tablet friability
• Dose loading
• Packaging requirements
• Unit-dose protection

Possible approaches include polymeric coating, ion-exchange resins, lipid barriers, cyclodextrin complexes, and multiparticulate systems. The formulation must disintegrate quickly without delaying dissolution or creating unacceptable mouthfeel.

An ODT would likely be more suitable for a 505(b)(2) strategy if it offers a clinically or practically meaningful benefit beyond a conventional generic. An ANDA pathway may remain available if the product can demonstrate pharmaceutical equivalence and bioequivalence to the reference product.

4. Liquid formulation

An oral solution or suspension could address patients who cannot swallow solid dosage forms. The formulation is technically difficult because of:

• Acetaminophen solubility and precipitation risk
• Butalbital solubility limitations
• Caffeine solubility and crystallization behavior
• Preservative compatibility
• pH control
• Container adsorption
• Chemical stability
• Sedimentation and redispersibility for suspensions
• Taste and alcohol content

A suspension may be more practical than a true solution if the full dose cannot be solubilized at an acceptable volume. Excipient options include suspending polymers, wetting agents, buffers, sweeteners, flavors, and preservatives. Butalbital’s controlled-substance status makes dose-measuring accuracy and child-resistant packaging particularly important.

A liquid product may have stronger lifecycle-management value than another conventional tablet because it can target swallowing difficulty, institutional use, and caregiver-administered dosing.

5. Capsule shell and capsule-fill optimization

Hard gelatin capsules are familiar but may have moisture, brittleness, and animal-origin concerns. Hypromellose capsules can support vegetarian positioning and may provide different moisture behavior.

Relevant development variables include:

• Powder flow into the capsule body
• Plug formation
• Weight variation
• Shell brittleness
• Moisture migration
• Capsule-lock integrity
• Colorant and titanium dioxide requirements
• Compatibility with high-speed filling

A capsule product can also use pellets or mini-tablets to improve blend uniformity and support future modified-release or taste-masked designs.

6. Excipient substitution and supply-chain resilience

Many generic manufacturers can create commercial value by removing excipients associated with:

• Latex or animal-origin concerns
• Colorant sensitivity
• Lactose intolerance concerns
• Titanium dioxide restrictions in selected markets
• Sodium lauryl sulfate sensitivity
• Nitrosamine or elemental-impurity risk
• Single-source supply exposure

Excipient substitution must preserve dissolution, stability, bioequivalence, and manufacturability. A label with fewer excipients may improve procurement and institutional acceptance, but the product must not imply that conventional excipients are unsafe without supporting evidence.

What formulation patents could protect a new product?

The strongest patent opportunities would likely involve a technical problem that is difficult to solve with routine formulation work.

Potential claim categories include:

Claim area	Example commercial objective
Taste-masked particles	Improved patient acceptability
Fast-disintegrating tablet	Swallowing assistance
Stable oral liquid	Pediatric, geriatric, or institutional use
Modified-release system	Reduced dosing frequency or peak-related adverse effects
Abuse-deterrent formulation	Reduced crushing, extraction, or dose dumping
Low-segregation blend	Improved content uniformity
Moisture-stable capsule	Longer shelf life and broader distribution
Impurity-control process	Better stability and reduced degradation
Specialized packaging	Dosing accuracy and diversion control

Patent strength depends on reproducible technical effects, comparative data, and claim breadth. A patent limited to routine excipient substitution is vulnerable if the substitution would have been obvious to a skilled formulator. Stability data, dissolution profiles, abuse-deterrence testing, and manufacturability data can improve the defensibility of a formulation patent.

How do Paragraph IV challenges affect this market?

For a standard ANDA against an approved reference product, Paragraph IV certification is relevant only if the reference product has listed patents. If no blocking patent is listed, an applicant may instead submit a Paragraph III certification or certify that no relevant patent information is listed, depending on the Orange Book record and application circumstances.[3,6]

The practical litigation risk for this mature combination is generally lower than for a recently approved branded drug, but it can reappear when:

• A branded sponsor launches a new 505(b)(2) formulation.
• A novel abuse-deterrent product receives patents.
• A liquid or ODT is supported by newly listed formulation patents.
• A method-of-use patent is listed for a specific approved indication.

Generic companies should separate the risk of patent litigation from the risk of FDA review delay, controlled-substance manufacturing requirements, and commercial access limitations.

Which companies are challenging or competing in this market?

Competition is fragmented across generic manufacturers, contract development and manufacturing organizations, and branded-label suppliers. Market participants may include companies with established portfolios in controlled substances and analgesics, as well as generic manufacturers that already produce acetaminophen combinations.

The competitive variables are:

• Approved strength and dosage form
• DEA manufacturing quota and controlled-substance compliance
• Product availability
• Wholesale acquisition price
• Reimbursement status
• Authorized-generic arrangements
• National wholesaler access
• Shortage history
• Packaging and labeling quality
• Ability to support hospital and retail channels

A smaller supplier can compete through dependable supply, dual-source excipients, responsive customer service, or a differentiated dosage form. Price alone is unlikely to produce durable advantage in a crowded immediate-release market.

What FDA regulatory issues affect commercial launch?

The regulatory route determines both cost and differentiation.

ANDA pathway

An ANDA requires demonstration of pharmaceutical equivalence and bioequivalence to the reference product. Critical controls include:

• Assay and content uniformity
• Dissolution across relevant media
• Impurity profile
• Stability
• Microbial quality, where applicable
• Container-closure performance
• Inactive-ingredient acceptability
• Labeling consistency

FDA’s Inactive Ingredient Database can support excipient selection, but the database does not eliminate the need to justify route, dosage form, maximum daily exposure, and formulation-specific use.[7]

505(b)(2) pathway

A 505(b)(2) application may be appropriate for a novel liquid, ODT, modified-release product, or abuse-deterrent formulation. The sponsor must define the new clinical or pharmaceutical contribution and generate data sufficient to support the proposed labeling.

A novel dosage form creates a larger commercial opportunity but also increases development cost, clinical risk, manufacturing complexity, and intellectual-property exposure.

What generic entry risks exist?

Generic entry risk is high for conventional tablets and capsules because:

• The active ingredients are old.
• Multiple manufacturers can formulate the product.
• Excipients are widely available.
• Patients and prescribers are familiar with the dosage forms.
• Therapeutic substitution is commercially feasible.

Risk is lower for a differentiated liquid, ODT, modified-release, or abuse-deterrent product if the product has meaningful patents, regulatory exclusivity, reliable supply, and payer acceptance.

Butalbital’s controlled-substance classification can restrict market participation. Manufacturers must manage DEA registration, quotas, theft prevention, suspicious-order controls, and inventory reconciliation. These requirements create a modest operational barrier but do not replace patent protection.

How does this product compare with competing headache medicines?

Product category	Main advantage	Main limitation	Excipient opportunity
Butalbital/acetaminophen/caffeine	Established use and familiar combination	Dependence, withdrawal, medication-overuse risk	Liquid, ODT, taste masking, abuse deterrence
Acetaminophen alone	Lower formulation complexity	May provide inadequate relief for some patients	Pediatric liquid and rapid-disintegration formats
NSAID products	Broad generic availability	Gastrointestinal and renal risk	Gastro-resistant and fast-release systems
Triptans	Migraine-specific positioning	Prescription and disease-specific use	ODT, nasal, and oral absorption platforms
Newer migraine agents	Lower abuse and overuse concerns in some products	Higher cost and payer restrictions	Lifecycle and delivery-system reformulation

The combination’s commercial position is strongest where prescribers continue to value a familiar, low-cost product and where a supplier can maintain availability. It is weaker in segments prioritizing noncontrolled therapies or migraine-specific treatments.

What is the revenue exposure and commercial upside?

Revenue exposure is usually concentrated in volume rather than high unit price. A conventional generic can generate stable revenue if it wins a meaningful share of pharmacy and institutional purchasing, but price erosion and multiple suppliers limit margin expansion.

The highest-value opportunities are:

1. A reliable conventional generic with low manufacturing cost.
2. A formulation with fewer supply-chain vulnerabilities.
3. A liquid or ODT with a clear patient-use benefit.
4. An abuse-deterrent or controlled-release product supported by enforceable patents.
5. A contract-manufacturing or licensing platform for smaller branded suppliers.
6. A private-label product with differentiated packaging and controlled-substance compliance.

Licensing opportunities may involve a formulation patent, a proprietary taste-masking system, a specialized capsule platform, or a manufacturing process. The licensee should evaluate freedom to operate across the active ingredients, excipients, equipment, packaging, and proposed claims. There is no obvious need to license the basic combination itself.

What is the overall patent strength of the product estate?

The patent estate for conventional butalbital, acetaminophen, and caffeine tablets or capsules is weak because the product is old, genericized, and based on widely used excipients. A new formulation estate could be moderate or strong if it has:

• A clearly defined technical problem
• Comparative data against conventional products
• Narrow but commercially meaningful claims
• Process claims that are difficult to design around
• Stable supply of specialized excipients
• Regulatory exclusivity or a protected 505(b)(2) label
• Claims covering the dosage form and manufacturing process

The most defensible assets are likely to be formulation and process patents tied to measurable performance, rather than broad claims covering routine excipient combinations.

Key Takeaways

• Conventional immediate-release tablets and capsules are mature generic products with limited basic patent value.
• Excipient strategy should focus on content uniformity, acetaminophen load, dissolution, stability, taste, and manufacturing efficiency.
• Liquid, ODT, modified-release, and abuse-deterrent products offer the strongest differentiation potential.
• Butalbital’s Schedule III status creates operational and compliance barriers but does not create market exclusivity.
• FDA Orange Book, DailyMed, USPTO, and FDA inactive-ingredient records should be reviewed for the specific reference product and proposed formulation.
• A 505(b)(2) strategy may provide greater commercial differentiation than another standard ANDA, but it carries higher development and regulatory costs.
• Formulation patents are most credible when supported by comparative performance and non-routine technical results.
• The strongest near-term commercial model is a reliable generic platform combined with a differentiated lifecycle product.

FAQs

Can lactose be removed from a butalbital, acetaminophen, and caffeine tablet?

Yes. Lactose can generally be replaced with microcrystalline cellulose, mannitol, starch, or a co-processed excipient, subject to dissolution, stability, bioequivalence, and manufacturability requirements.

Is an abuse-deterrent version commercially viable?

Potentially, but the product would require a credible abuse-deterrence profile, regulatory support, clinical and in vitro data as appropriate, and patents that cover the formulation or manufacturing method. Controlled-substance status alone does not establish abuse deterrence.

Can this combination be developed as an oral solution?

Yes, but precipitation, taste, chemical stability, preservative compatibility, and dose-measurement accuracy are major development risks. A suspension may be more practical than a true solution.

Would an orally disintegrating tablet receive new patent protection?

It could, but an ODT is not automatically patentable. Protection would depend on novel formulation architecture, technical performance, manufacturing method, or a demonstrated benefit that is not an obvious variation of known ODT technology.

Does the combination require biosimilar development?

No. Butalbital, acetaminophen, and caffeine are small-molecule active ingredients. The relevant pathways are generally ANDA or 505(b)(2), not the biologics license application and biosimilar pathways.

References

1. U.S. Drug Enforcement Administration. (2024). Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling
2. U.S. Food and Drug Administration. (2024). Fioricet prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
4. U.S. Food and Drug Administration. (2024). Guidance for industry: Applications covered by section 505(b)(2). https://www.fda.gov/
5. National Library of Medicine. (2024). DailyMed: Butalbital, acetaminophen, and caffeine product labeling. https://dailymed.nlm.nih.gov/
6. U.S. Food and Drug Administration. (2024). ANDA submissions: Refuse-to-receive standards. https://www.fda.gov/
7. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/